Radiopharm Theranostics Limited reported earnings results for the half year ended December 31, 2023. For the half year, the company reported net loss was AUD 24.76 million compared to AUD 12.55 million a year ago. Basic loss per share from continuing operations was AUD 0.0721 compared to AUD 0.0454 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.04 AUD | +2.56% | 0.00% | -45.95% |
08/05 | Radiopharm Theranostics to be Featured in Healthcare Events Hosted by B. Riley Securities | MT |
29/02 | Radiopharm Theranostics Doses First Patient in Pancreatic Cancer Imaging Study | MT |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-45.95% | 11.93M | |
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
+7.68% | 166B |
- Stock Market
- Equities
- RAD Stock
- News Radiopharm Theranostics Limited
- Radiopharm Theranostics Limited Reports Earnings Results for the Half Year Ended December 31, 2023